Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:280:263-281.
doi: 10.1007/164_2022_591.

Economics and Precision Medicine

Affiliations

Economics and Precision Medicine

Katherine Payne et al. Handb Exp Pharmacol. 2023.

Abstract

Introducing precision medicine strategies into routine practice will require robust economic evidence. Decision-makers need to understand the value of a precision medicine strategy compared with alternative ways to treat patients. This chapter describes health economic analysis techniques that are needed to generate this evidence. The value of any precision medicine strategy can be demonstrated early to inform evidence generation and improve the likelihood of translation into routine practice. Advances in health economic analysis techniques are also explained and their relevance to precision medicine is highlighted. Ensuring that constraints on delivery are resolved to increase uptake and implementation will improve the value of a new precision medicine strategy. Empirical methods to quantify stakeholders' preferences can be effective to inform the design of a precision medicine intervention or service delivery model. A range of techniques to generate relevant economic evidence are now available to support the development and translation of precision medicine into routine practice. This economic evidence is essential to inform resource allocation decisions and will enable patients to benefit from cost-effective precision medicine strategies in the future.

Keywords: Budget impact analysis; Cost-effectiveness analysis; Decision-analytic model; Discrete choice experiment; Economic evaluation; Microcosting; Pharmacoeconomics; Stated preferences; Value of implementation; Value of information.

PubMed Disclaimer

References

    1. Abel L, Shinkins B, Smith A, Sutton A, Sagoo G, Uchegbu I, Allen A, Graziadio S, Moloney E, Yang Y, Hall P (2019) Early economic evaluation of diagnostic technologies: experiences of the NIHR diagnostic evidence co-operatives. Med Decis Making 39:857–866 - PubMed
    1. Annemans L, Redekop K, Payne K (2013) Current methodological issues in the economic assessment of personalized medicine. Value Health 16:S20–S26 - PubMed
    1. Basu A, Meltzer D (2005) Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 24:751–773 - PubMed
    1. Bowling A (2004) Measuring health: a review of quality of life measurement scales, 3rd edn. Open University Press, Maidenhead
    1. Brazier J, Ratcliffe J, Salomon J, Tsuchiya A (2017) Measuring and valuing health benefits for economic evaluation, 2nd edn. Oxford University Press, Oxford

LinkOut - more resources